Journal of Clinical and Experimental Hematopathology

Scope & Guideline

Catalyzing Global Collaboration in Hematopathology.

Introduction

Welcome to your portal for understanding Journal of Clinical and Experimental Hematopathology, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1346-4280
PublisherJAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
Support Open AccessYes
CountryJapan
TypeJournal
Convergefrom 2006 to 2016, from 2019 to 2024
AbbreviationJ CLIN EXP HEMATOP / J. Clin. Exp. Hematop.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressNAGOYA UNIV GRAD SCH MEDICINE, HIGH-TECHNOLOGY APPLICATION MEDICINE, CLINICAL PATHOPHYSI, NAGOYA 466-8550, JAPAN

Aims and Scopes

The Journal of Clinical and Experimental Hematopathology primarily focuses on advancing the understanding and treatment of hematologic malignancies. It serves as a platform for sharing innovative research findings, clinical experiences, and insights into the pathology of blood-related disorders, particularly lymphomas and leukemias.
  1. Hematologic Malignancies Research:
    The journal emphasizes research on various hematologic malignancies, including lymphomas, leukemias, and plasma cell disorders. It covers both clinical and experimental studies that contribute to the understanding of these diseases.
  2. Clinical Case Reports and Reviews:
    A significant portion of the journal includes case reports and literature reviews that provide insights into rare and complex cases, thereby enhancing clinical knowledge and guiding treatment strategies.
  3. Pathological Insights and Diagnostics:
    The journal highlights the importance of pathology in diagnosing hematologic disorders. It publishes studies focusing on histopathological evaluations, immunohistochemistry, and molecular techniques that assist in accurate diagnosis.
  4. Therapeutic Advances and Clinical Trials:
    Research on new therapeutic approaches, including novel drug treatments and clinical trial outcomes, is a core focus. The journal aims to disseminate findings that can influence treatment protocols and improve patient outcomes.
  5. Tumor Microenvironment and Immune Response:
    There is a growing emphasis on the role of the tumor microenvironment and immune interactions in hematologic diseases. The journal explores how these factors affect disease progression and treatment responses.
The Journal of Clinical and Experimental Hematopathology has been evolving, with several themes emerging as increasingly prominent in recent publications. This section outlines the trending and emerging scopes that reflect the current interests and advancements in the field.
  1. Precision Medicine and Targeted Therapies:
    There is a significant trend towards research focused on precision medicine and targeted therapies for hematologic malignancies. This includes studies on specific genetic mutations, biomarkers, and tailored treatment approaches that enhance efficacy and minimize toxicity.
  2. Immunotherapy and CAR T-cell Therapy:
    Immunotherapy, particularly CAR T-cell therapy, is gaining prominence in the journal's publications. Research exploring the mechanisms, efficacy, and safety of these therapies is increasingly relevant as they become standard treatment options for various hematologic cancers.
  3. Tumor Microenvironment Studies:
    Emerging themes related to the tumor microenvironment, including the interplay between tumor cells and immune cells, are becoming a focal point. This research is crucial for understanding disease progression and developing new therapeutic strategies.
  4. Patient-Centered Outcomes and Quality of Life:
    Research that addresses patient perspectives, treatment satisfaction, and quality of life is on the rise. This trend highlights the importance of incorporating patient-reported outcomes into clinical practice and research.
  5. Novel Biomarkers for Diagnosis and Prognosis:
    The discovery and validation of novel biomarkers for the diagnosis and prognosis of hematologic malignancies are increasingly featured. Such studies are essential for improving diagnostic accuracy and tailoring treatment strategies.

Declining or Waning

While the Journal of Clinical and Experimental Hematopathology maintains a broad focus on hematologic disorders, certain themes have begun to decline in prominence. This section highlights these waning scopes based on recent publication trends.
  1. Basic Laboratory Techniques:
    There appears to be a declining focus on basic laboratory techniques and methodologies compared to more advanced and specialized studies. Research that centers solely on traditional laboratory methods without novel insights or applications has become less common.
  2. Generalized Reviews without Novel Insights:
    The journal has seen a decrease in generalized review articles that do not provide new perspectives or significant updates on existing knowledge. There is a trend towards more focused reviews that address specific questions or emerging issues.
  3. Older Treatment Protocols:
    Research centered around older treatment protocols, especially those that have been largely replaced by newer regimens or therapies, is becoming less frequent. The journal is shifting towards studies that investigate contemporary treatment strategies and their outcomes.
  4. Epidemiological Studies without Clinical Relevance:
    Epidemiological studies that lack direct clinical relevance or applicability to current treatment practices are being published less frequently. The focus is moving towards studies that bridge the gap between epidemiology and clinical application.

Similar Journals

INTERNATIONAL JOURNAL OF HEMATOLOGY

Fostering Global Insights in Blood Research
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Hematologie

Connecting Researchers and Clinicians in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

Journal of Hematology & Oncology

Elevating Knowledge in Cancer and Hematological Studies
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Hematology & Oncology, published by BMC, is a leading open-access journal dedicated to the dynamic fields of hematology and oncology, with a continuous publication record since 2008. Based in the United Kingdom, this prestigious journal provides a platform for groundbreaking research, encompassing topics that span cancer research, hematological disorders, and molecular biology. With a remarkable Q1 ranking in multiple categories including Cancer Research, Hematology, Molecular Biology, and Oncology for 2023, it stands as a significant contributor to the scientific community. The journal's rigorous peer-review process ensures the dissemination of high-quality studies that drive advancements in these critical areas of medicine, boasting an impressive Scopus rank in the top echelons of its fields. As an open-access publication, it promotes widespread accessibility and sharing of knowledge, making it an indispensable resource for researchers, clinicians, and students striving to make advancements in understanding and treating hematological and oncological diseases.

Egyptian Journal of Haematology

Exploring Breakthroughs in Blood Health and Disease
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Journal of Hematopathology

Advancing knowledge in hematopathology.
Publisher: SPRINGER HEIDELBERGISSN: 1868-9256Frequency: 4 issues/year

The Journal of Hematopathology, published by SPRINGER HEIDELBERG, serves as a vital resource in the fields of hematology, histology, and pathology. Established in 2008, this peer-reviewed journal aims to foster the exchange of knowledge among researchers, clinicians, and students by publishing original articles, reviews, and case studies that contribute to the understanding of hematopathological disorders. While the journal currently ranks in the fourth quartile in various categories including hematology and histology, it positions itself as a platform for emergent research and insights, addressing the evolving landscape of blood-related diseases. Although not an open access journal, it provides crucial access to research findings for professionals looking to stay abreast of developments in pathologic diagnostics and therapeutic strategies. As it continues to grow, the journal remains committed to enhancing the knowledge base and scientific discourse in hematopathology.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Your Essential Resource for Clinical Pathology Insights
Publisher: OXFORD UNIV PRESS INCISSN: 0002-9173Frequency: 12 issues/year

The American Journal of Clinical Pathology, published by Oxford University Press Inc, stands as a vital resource in the fields of pathology and clinical medicine. With a rich history dating back to 1945 and an impressive impact factor reflected in its Q1 ranking in Pathology and Forensic Medicine, this journal serves as a cornerstone for researchers and professionals seeking to advance their knowledge and practice. Covering a breadth of topics within the discipline, it is recognized in 2023 as ranked #24 out of 208 in its category, highlighting its esteemed reputation within the scientific community. Although the journal does not currently offer open access, its rigorous peer-reviewed articles and cutting-edge research make it an essential addition to any academic or clinical library. The ISSN for print version is 0002-9173, with an E-ISSN of 1943-7722 available for digital access. Researchers, students, and practitioners alike will benefit from its comprehensive scope and commitment to disseminating high-quality scientific inquiry.

Turkish Journal of Pathology

Your Gateway to Cutting-Edge Pathological Discoveries
Publisher: FEDERATION TURKISH PATHOLOGY SOCISSN: 1018-5615Frequency: 3 issues/year

Turkish Journal of Pathology, published by the Federation Turkish Pathology Society, stands as a vital platform for disseminating high-quality research in the field of pathology and forensic medicine. With an ISSN of 1018-5615 and an E-ISSN of 1309-5730, this journal has been an open-access publication since 2013, ensuring that cutting-edge findings are readily available to the global community. Based in Turkey, it aims to contribute significantly to the advancement of pathology as it converges from 2010 to 2024, currently holding a Q3 quartile ranking in its category according to 2023 metrics. As it ranks #129 out of 208 in the Scopus database for Medicine, Pathology, and Forensic Medicine, it offers researchers, professionals, and students invaluable insights and innovative studies that address critical developments in the field. The Turkish Journal of Pathology fosters collaboration and knowledge-sharing, making it an essential resource for anyone involved in pathology research and practice.

Hematology Reports

Exploring breakthroughs in blood health.
Publisher: MDPIISSN: 2038-8322Frequency: 4 issues/year

Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.

Hematology Transfusion and Cell Therapy

Elevating standards in cell therapy and transfusion science.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Hematology

Empowering Research: Your Gateway to Hematology Excellence
Publisher: TAYLOR & FRANCIS LTDISSN: 1024-5332Frequency: 1 issue/year

Hematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.